Clinical Trial Update: Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers [Phase 3]

View source ↗

Summary

Phase 3 Lung-MAP trial update evaluating nivolumab with or without ipilimumab as second-line therapy for recurrent Stage IV squamous cell carcinoma of the lung …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Squamous Cell Carcinoma of the Lung

Drugs mentioned

• OPDIVO (nivolumab)
• Yervoy (ipilimumab)

Snippet

Sponsor: SWOG Cancer Research Network | Conditions: Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC v7 | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2022-01-11